Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

When there are higher than normal amounts of HER2 on breast cancer cells, the cancer is called HER2 positive. And these cancer cells can grow more rapidly than other breast cancers. HER2 positive ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Tumors, such as some breast and ovarian cancers, can express the marker HER2. HER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new ...